VSD Closure (Ventricular Septal Defect) — Cost, Top Hospitals & Success Rates | MyMedicPlus

A ventricular septal defect (VSD) is an abnormal opening or hole in the interventricular septum — the muscular wall that separates the left and right ventricles of the heart. VSDs are the most common congenital heart defect, occurring in approximately 3–5 per 1,000 live births and accounting for 30–40% of all congenital cardiac anomalies. They may also develop as a complication of acute myocardial infarction (post-infarction VSD) or cardiac trauma.

The interventricular septum has four anatomical regions: the membranous (perimembranous), muscular (trabecular), inlet (atrioventricular canal type), and outlet (supracristal or conal) sections. Perimembranous VSDs are the most common type (~70% of cases), followed by muscular VSDs (~20%). The location, size, and hemodynamic consequence of the defect determine clinical presentation and the urgency of repair.

In a VSD, blood shunts from the high-pressure left ventricle to the lower-pressure right ventricle (left-to-right shunt). Large defects cause significant volume overload of the right ventricle and pulmonary vasculature, leading to pulmonary hypertension, heart failure, arrhythmias, and — if untreated — the irreversible pulmonary vascular disease known as Eisenmenger syndrome. Small VSDs may close spontaneously in childhood or remain hemodynamically insignificant throughout life.

VSD closure is performed by two primary approaches: open-heart surgical repair using cardiopulmonary bypass, and transcatheter device closure — a minimally invasive technique using a catheter passed through a blood vessel in the groin. The goal of closure is to eliminate the abnormal shunt, relieve volume overload, prevent pulmonary hypertension progression, and restore normal cardiovascular physiology.

This guide provides comprehensive, evidence-based information on VSD closure to help patients, parents, and caregivers understand the full spectrum of diagnosis, treatment, risks, recovery, and expected outcomes.

VSD closure procedures address defects across multiple clinical scenarios:

Congenital VSDs by Type

• Perimembranous (membranous) VSD: Located in the upper part of the interventricular septum near the aortic valve. Most common type; may be associated with aortic valve prolapse requiring additional repair. Some close spontaneously in early childhood.
• Muscular VSD: Located within the muscular body of the septum; may be multiple (so-called 'Swiss cheese' septum). Small muscular VSDs frequently close spontaneously; large or multiple defects may require surgery or device closure.
• Inlet (atrioventricular canal-type) VSD: Located in the posterior, inferior septum near the tricuspid valve. Associated with Down syndrome. Usually requires surgical repair as part of complete AV canal correction.
• Outlet (supracristal/conal) VSD: Located beneath the pulmonary and aortic valves; carries a high risk of progressive aortic valve regurgitation. Surgical closure is generally recommended even for small defects due to this complication risk.

Acquired VSDs

• Post-myocardial infarction VSD: A rare but life-threatening complication of acute MI, occurring when ischemic rupture of the interventricular septum creates an acute VSD. These patients are critically ill, often in cardiogenic shock, and require urgent or emergent closure — mechanical circulatory support (IABP, Impella, ECMO) is frequently needed as a bridge to repair.
• Traumatic VSD: Penetrating or blunt cardiac trauma can create a VSD, requiring timely repair once the patient is stabilized.

Hemodynamically Significant VSDs

The primary indications for closure are a pulmonary-to-systemic flow ratio (Qp:Qs) of greater than 2:1, evidence of left ventricular volume overload, pulmonary artery pressure elevation, or progressive symptoms of heart failure. VSDs with Qp:Qs less than 1.5:1 and normal pulmonary pressures may be managed with observation in some guidelines.

The decision to close a VSD depends on defect characteristics, the patient's symptoms, hemodynamic measurements, and pulmonary vascular resistance:

Indications for Closure

• Symptomatic VSD with heart failure, failure to thrive (in infants), or reduced exercise capacity
• Large VSD with left-to-right shunt causing volume overload (Qp:Qs ≥ 2:1)
• Pulmonary arterial pressure elevated but pulmonary vascular resistance still reversible (PVR/SVR ratio < 0.5)
• Supracristal VSD of any size (due to risk of aortic regurgitation)
• VSD with associated aortic valve prolapse or regurgitation
• Recurrent endocarditis related to the VSD jet lesion

Contraindications to Closure

• Eisenmenger syndrome: Fixed, irreversible pulmonary hypertension with reversed (right-to-left) shunting represents an absolute contraindication to VSD closure; closure in this setting can precipitate right heart failure and death. These patients require pulmonary vasodilator therapy and consideration for heart-lung transplantation.
• Severe comorbidities precluding anesthesia and surgery
• Very small, restrictive VSDs with Qp:Qs < 1.5:1 and no hemodynamic consequence may be managed conservatively with endocarditis prophylaxis guidance

Spontaneous Closure

Small muscular and perimembranous VSDs frequently close spontaneously during the first 2–5 years of life as the muscular septum grows and the defect is covered by fibrous tissue. Up to 75% of small muscular VSDs and 40% of small perimembranous VSDs close without intervention. Close echocardiographic surveillance is maintained during this period.

Pre-operative Evaluation

Assessment includes transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), cardiac catheterization for pressure and resistance measurements in complex cases, and chest X-ray or cardiac MRI to quantify volumes. In post-MI VSDs, coronary angiography is essential.

Two main approaches exist for VSD closure, with the choice determined by defect type, location, size, patient age and weight, and centre expertise:

1. Open-Heart Surgical Repair

The traditional and most versatile approach, applicable to all VSD types and sizes. The patient is placed on cardiopulmonary bypass (heart-lung machine), the heart is stopped with cardioplegia, and the surgeon accesses the defect through a ventriculotomy (incision in the heart muscle) or through the atrium or aorta to avoid a ventricular scar. The defect is closed with:

• Direct suture closure: For small defects with firm tissue edges
• Patch repair: For large or complex defects; a synthetic patch (Dacron or PTFE) or a biological patch (bovine pericardium, autologous pericardium) is sutured over the defect

The surgeon also addresses associated lesions (aortic regurgitation, tricuspid regurgitation, other intracardiac defects) during the same bypass run. A midline sternotomy (chest incision) is the standard access, though minimally invasive right thoracotomy or robotic approaches are available at specialized centres.

2. Transcatheter Device Closure

A minimally invasive catheter-based technique suitable for selected muscular VSDs and some perimembranous VSDs. Under general anesthesia and fluoroscopic/echocardiographic guidance, a catheter is advanced from the femoral vein (or artery) through the defect. A double-disc occlusion device — most commonly the Amplatzer Muscular VSD Occluder or Amplatzer Membranous VSD Occluder — is deployed to straddle the defect and seal it. The device is made of a nitinol wire mesh that allows tissue ingrowth over 4–6 months, achieving complete sealing. Advantages include avoidance of cardiopulmonary bypass, shorter hospital stays, and faster recovery. Limitations include restriction to specific defect types/locations, minimum weight requirements (>5 kg generally), and risk of complete heart block (higher for perimembranous devices).

3. Hybrid Procedure

In neonates or small infants with multiple muscular VSDs or unfavorable anatomy for standard catheter closure, a hybrid approach combining surgical epicardial access with catheter-delivered device closure avoids the need for full cardiopulmonary bypass. The surgeon gains direct access to the heart surface and guides a device delivery sheath into position under direct vision and echocardiographic guidance.

4. Transcatheter Closure of Post-MI VSD

Emergency transcatheter closure using dedicated devices (e.g., Amplatzer Post-Infarct Muscular VSD Occluder) is used in selected hemodynamically unstable post-MI VSD patients when surgery is too high risk, typically combined with mechanical circulatory support.

Timely closure of a hemodynamically significant VSD provides substantial short-term and long-term benefits:

Cardiovascular Benefits

• Elimination of the left-to-right shunt: Closure immediately restores normal flow physiology, removing the volume overload burden on the left ventricle and right heart.
• Prevention of pulmonary hypertension: Early closure (ideally before 2 years of age in large VSDs) prevents the development of irreversible pulmonary vascular disease.
• Improvement or normalization of left ventricular function: Relief of chronic volume overload leads to LV remodeling with reduction in LV dilation over weeks to months.
• Prevention of aortic regurgitation: Closure of outlet and perimembranous VSDs eliminates the Venturi effect that draws the aortic cusp toward the defect.

Symptomatic Benefits

• Resolution of heart failure symptoms (breathlessness, sweating during feeds in infants, failure to thrive)
• Normalization of exercise tolerance and quality of life
• Elimination of recurrent chest infections associated with pulmonary overcirculation
• Reduction in endocarditis risk (though lifelong dental hygiene is still emphasized)

Long-term Outcomes

The long-term survival after successful VSD closure approaches that of the general population when repair is performed before significant pulmonary hypertension develops. Data from multi-centre follow-up studies (20–30 years post-repair) confirm excellent survival, normal growth and neurodevelopment in children, and durable closure results with very low rates of residual defects or reoperation.

VSD closure carries procedure-specific and general surgical risks. The risk profile differs between open surgery and catheter-based closure:

Surgical (Open-Heart) Risks

• Residual VSD: Occurs in 5–10% of cases, usually small and hemodynamically insignificant; large residual defects may require reoperation.
• Complete heart block: Damage to the atrioventricular conduction system (His bundle) during patch placement, occurring in 1–3% of perimembranous VSD repairs; may require permanent pacemaker implantation.
• Aortic regurgitation: Risk during perimembranous VSD repair if the aortic valve is not carefully protected.
• Wound complications: Sternal wound infection (1–2%), especially in immunocompromised patients.
• Cardiopulmonary bypass complications: Neurological injury, inflammatory response, arrhythmias, bleeding, renal dysfunction.
• Mortality: Operative mortality for isolated VSD repair in elective settings is less than 1% at experienced centres for children and adults with normal pulmonary vascular resistance.

Catheter-Based Device Closure Risks

• Complete heart block: Higher rate than surgical repair for perimembranous VSDs (2–5% with membranous devices); may require pacemaker and/or device retrieval.
• Device embolization: Rare (<1%); the device dislodges and migrates to the pulmonary vasculature or aorta, requiring emergency retrieval.
• Residual shunt: Small residual shunts around the device are common initially (30–40%) but usually close with tissue ingrowth over 3–6 months.
• Haemolysis: Turbulent flow around a partially occluded defect can cause mechanical red cell destruction.
• Vascular access complications: Haematoma, arteriovenous fistula, or vascular injury at the femoral access site.
• Aortic or tricuspid valve injury: Device impingement on adjacent valve structures.

Recovery from VSD closure is well-defined, with close surveillance required particularly in the first year after repair:

Surgical Recovery

After open-heart repair, patients typically spend 1–2 days in the pediatric or adult cardiac ICU before transfer to the ward. Total hospital stay is 5–7 days. A drain is placed in the chest to remove excess fluid and removed within 24–48 hours. Pain management includes IV analgesia transitioning to oral medications. Infants and children resume normal feeding within 2–3 days. Sternal precautions (no lifting with arms for 6–8 weeks in adults) are important to allow the sternum to heal.

Device Closure Recovery

Patients undergoing transcatheter device closure spend 1–2 nights in hospital for monitoring of heart rhythm and access site. Aspirin (3–5 mg/kg/day, max 100 mg) is prescribed for 6 months to prevent thrombus formation on the device until full endothelialization occurs. Activity restriction is less stringent than surgical repair.

Post-operative Follow-up Schedule

• 6 weeks: Clinical review, chest X-ray, ECG, and echocardiogram to confirm device/patch position, residual shunt status, and cardiac dimensions
• 6 months: Echocardiogram to assess device endothelialization (device closure) or ventricular remodeling (surgical repair); repeat catheterization if residual hemodynamic concerns
• 1 year and annually: Clinical review and echocardiogram; ECG for conduction surveillance
• Infective endocarditis prophylaxis: Recommended for 6 months post-closure in both surgical and device patients (or longer if residual defect persists adjacent to the patch or device)

Children can generally return to school within 3–4 weeks after surgical repair and 1 week after device closure. Full physical activity including sports is usually permitted by 3 months post-surgery after a normal exercise test.

The cost of VSD closure varies substantially by approach, centre expertise, geographic location, and associated comorbidities. Below is an overview of typical cost ranges:

Cost Components

• Cardiac surgery or interventional cardiology team fees
• Anaesthesiology and perfusionist fees (for surgical repair)
• Hospital and ICU facility charges
• Device cost: transcatheter occlusion devices range from USD 2,000–5,000
• Cardiopulmonary bypass and disposables (surgical approach)
• Pre-operative diagnostic workup (echocardiography, cardiac catheterization)
• Post-operative medications and follow-up echocardiograms

Estimated Costs by Region

• United States: USD 30,000–80,000 for open surgical repair; USD 15,000–40,000 for device closure (covered by most private and government insurance for congenital heart disease)
• United Kingdom (NHS): Available without direct cost for UK residents; private sector GBP 15,000–35,000
• India: USD 4,000–10,000 for surgical repair at NABL/JCI-accredited hospitals; USD 2,500–6,000 for device closure. Premier centres include AIIMS New Delhi, Narayana Health, and Fortis Escort Heart Institute.
• Singapore: USD 12,000–25,000; National Heart Centre Singapore is a regional referral centre
• Thailand: USD 8,000–18,000; Bumrungrad International and Bangkok Heart Hospital
• Turkey: USD 6,000–15,000; rapidly growing congenital cardiac surgery expertise

Insurance Considerations

Congenital VSD is uniformly covered by health insurance in most countries with national health schemes. In private insurance markets, pre-authorization is required. Medical tourism to India, Thailand, or Turkey is a cost-effective option for patients without insurance coverage, with savings of 60–80% compared to US or UK private rates while maintaining high-quality outcomes at accredited centres.

Not all VSDs require immediate closure. Management alternatives include:

Watchful Waiting (Observation)

Small to moderate restrictive VSDs with a Qp:Qs of less than 1.5:1, normal pulmonary pressures, no symptoms, and no LV volume overload are managed conservatively with echocardiographic surveillance every 1–3 years. Many of these defects close spontaneously, particularly muscular VSDs in infants. Parents are educated about symptoms of increasing shunt (tachypnoea, poor feeding, excessive sweating) and signs of infective endocarditis.

Medical Management of Heart Failure

In infants with large VSDs and heart failure symptoms who are being optimized before surgery, medical management includes diuretics (furosemide, spironolactone) to reduce pulmonary congestion, ACE inhibitors to reduce afterload and shunt volume, and high-calorie formula to support growth. This therapy is a bridge to surgery, not a definitive treatment.

Pulmonary Arterial Banding

In rare cases where direct VSD closure is not feasible (very complex anatomy, critically ill neonate, multiple Swiss cheese VSDs), surgical banding of the main pulmonary artery reduces pulmonary blood flow and protects the pulmonary vasculature until definitive repair is possible at a later stage. This is a palliative strategy, not a curative one.

Pulmonary Vasodilator Therapy (Eisenmenger)

For patients who have already developed Eisenmenger syndrome, closure is contraindicated. Pulmonary vasodilator therapy with endothelin receptor antagonists (bosentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil), and prostacyclin analogues (iloprost, epoprostenol) can improve quality of life and functional capacity, and may extend survival. Heart-lung transplantation is the only definitive treatment for established Eisenmenger physiology.